This interactive symposium aims to position gastroenterologists to improve patient care and outcomes by increasing their awareness of NAFLD/NASH and enhancing their ability to engage patients with NAFLD in the clinical care pathway. Expert faculty will take a deep dive into late-stage clinical trials to address unmet clinical needs and the potential for new agents to address them. Gastroenterologists will benefit from reviewing the safety and efficacy data, as it will help prepare them to quickly integrate new agents into their practice when these agents become available.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Building Bridges, Closing Gaps in NASH Care: The Pivotal Role of Gastroenterologists
Are you up to date on the NAFLD clinical care pathway to provide optimal treatment for your patients?
Live
Broadcast
1.50 available credits
Information
October 22, 2023
08:00 PM - 09:30 PM PDT
Online
Share this program on:
Details
Presenters
Related
Comments
Overview
Program Schedule
- 8:00pm – 8:05pm: Welcome and Introductions
- 8:05pm – 8:10pm: Defining the Epidemic
- 8:10pm – 8:20pm: NAFLD/NASH: When to Think NAFLD
- 8:20pm – 8:50pm: Identifying and Engaging People with NAFLD/NASH in Care
- 8:50pm – 9:05pm: Current Standard of Care
- 9:05pm – 9:20pm: Updates on Phase 3 Clinical Trials of Emerging Therapies
- 9:20pm – 9:30pm: Closing Remarks and Audience Q&A
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Kimberly A. Brown, MD
Associate Medical Director
Henry Ford Hospital Transplant Institute
Professor of Medicine
Wayne State University
Detroit, MIConsulting Fees: Alexion, Gilead, Intercept, Mallinckrodt, Madrigal Pharmaceuticals, Salix
Research funding: SalixFaculty:
Mazen Noureddin, MD
Professor of Clinical Medicine
Lynda K. and David M. Underwood Center for Digestive Disorders
Department of Medicine
Sherrie & Alan Conover Center for Liver Disease & Transplantation
Houston Methodist Research Institute
Houston Methodist HospitalAdvisory board: Altimmune, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cytodyn, 89BIO, GSK, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Perspectum, Terns, Takeda
Principal investigator for a drug study: Allergan, Akero, Bristol-Myers Squibb Company, Gilead, Galectin, Genfit, GSK, Conatus, Corcept, Enanta, Madrigal Pharmaceuticals, Novartis, Novo Nordisk, Shire, Takeda, Terns, Viking, Zydus
Stockholder: Rivus Pharma, CIMA, Cytodyn, ChronWellAlina M. Allen, MD
Associate Professor of Medicine
Director of NAFLD Clinic
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MNConsulting Fees: Novo Nordisk
Research: National Institutes of Health (NIH), Novo Nordisk, Target PharmaReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- John Maeglin has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Report increased confidence in screening patients for nonalcoholic fatty liver disease (NAFLD)/ nonalcoholic steatohepatitis (NASH)
- Determine the next step for a patient being evaluated for NAFLD based on their non-invasive test for fibrosis
- Determine if a patient with a given transient elastography score is at risk for clinically significant fibrosis
- Interpret data from phase 3 clinical trials of novel therapies being investigated for the treatment of NASH
- Identify ways to activate the referral of patients with risk factors for NAFLD/NASH for NAFLD-specific evaluation and treatment
- State intent to change practice regarding activation of the referral base of clinicians in the best positions to identify patients with risk factors for NAFLD/NASH
Target Audience
This activity is designed to meet the educational needs of gastroenterologists, primary care physicians, nurse practitioners, and physician associates.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Details
Presenters
Related
Comments
Recommended
Overview
This interactive symposium aims to position gastroenterologists to improve patient care and outcomes by increasing their awareness of NAFLD/NASH and enhancing their ability to engage patients with NAFLD in the clinical care pathway. Expert faculty will take a deep dive into late-stage clinical trials to address unmet clinical needs and the potential for new agents to address them. Gastroenterologists will benefit from reviewing the safety and efficacy data, as it will help prepare them to quickly integrate new agents into their practice when these agents become available.
Program Schedule
- 8:00pm – 8:05pm: Welcome and Introductions
- 8:05pm – 8:10pm: Defining the Epidemic
- 8:10pm – 8:20pm: NAFLD/NASH: When to Think NAFLD
- 8:20pm – 8:50pm: Identifying and Engaging People with NAFLD/NASH in Care
- 8:50pm – 9:05pm: Current Standard of Care
- 9:05pm – 9:20pm: Updates on Phase 3 Clinical Trials of Emerging Therapies
- 9:20pm – 9:30pm: Closing Remarks and Audience Q&A
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Kimberly A. Brown, MD
Associate Medical Director
Henry Ford Hospital Transplant Institute
Professor of Medicine
Wayne State University
Detroit, MIConsulting Fees: Alexion, Gilead, Intercept, Mallinckrodt, Madrigal Pharmaceuticals, Salix
Research funding: SalixFaculty:
Mazen Noureddin, MD
Professor of Clinical Medicine
Lynda K. and David M. Underwood Center for Digestive Disorders
Department of Medicine
Sherrie & Alan Conover Center for Liver Disease & Transplantation
Houston Methodist Research Institute
Houston Methodist HospitalAdvisory board: Altimmune, Boehringer Ingelheim, Bristol-Myers Squibb Company, Cytodyn, 89BIO, GSK, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Perspectum, Terns, Takeda
Principal investigator for a drug study: Allergan, Akero, Bristol-Myers Squibb Company, Gilead, Galectin, Genfit, GSK, Conatus, Corcept, Enanta, Madrigal Pharmaceuticals, Novartis, Novo Nordisk, Shire, Takeda, Terns, Viking, Zydus
Stockholder: Rivus Pharma, CIMA, Cytodyn, ChronWellAlina M. Allen, MD
Associate Professor of Medicine
Director of NAFLD Clinic
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, MNConsulting Fees: Novo Nordisk
Research: National Institutes of Health (NIH), Novo Nordisk, Target PharmaReviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- John Maeglin has nothing to disclose.
- Andrea Mathis has nothing to disclose.
- Tim Person has nothing to disclose.
- Colleen Resnick has nothing to disclose.
- Susan Smith, MN, PhD has ownership interest in Hepion Pharmaceuticals.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Report increased confidence in screening patients for nonalcoholic fatty liver disease (NAFLD)/ nonalcoholic steatohepatitis (NASH)
- Determine the next step for a patient being evaluated for NAFLD based on their non-invasive test for fibrosis
- Determine if a patient with a given transient elastography score is at risk for clinically significant fibrosis
- Interpret data from phase 3 clinical trials of novel therapies being investigated for the treatment of NASH
- Identify ways to activate the referral of patients with risk factors for NAFLD/NASH for NAFLD-specific evaluation and treatment
- State intent to change practice regarding activation of the referral base of clinicians in the best positions to identify patients with risk factors for NAFLD/NASH
Target Audience
This activity is designed to meet the educational needs of gastroenterologists, primary care physicians, nurse practitioners, and physician associates.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Madrigal Pharmaceuticals.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Facebook Comments